Last checked at 
(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.
VAL201 has been developed as a collaboration between drug maker ValiRx and charity Cancer Research, and it is intended to treat hormone-dependent and hormone-independent prostate cancer.
The first-in-human phase 1/2 was amended in March to allow higher concentrations of the drug to be administered to patients and has shown "a safe and well tolerated profile" at these higher concentrations.
Moreover, data so far confirms preclinical findings and partially explains the reduction in prostate cancer progression.
The trial will be finalised as expected and a new trial will be developed to find the most effective regime for treatment.
ValiRx Chief Executive Satu Vanikka said: "We are delighted that our phase I/II trial of VAL201 has met its endpoints very well and that we are now able to use our peptide in demonstrating the efficacy of the VAL201 compound as a therapeutic product that has a large role to play in dealing with what is a nasty set of conditions in a better and more patient friendly way."
ValiRx shares were flat at 0.18 pence in London on Tuesday.
